p53, guardian of the genome
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53, famously known as the ‘Guardian of the genome’ plays a key role in manifestation of cellular senescence via several different mechanisms (Lane, 1992; Kastenhuber and Lowe, 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Lane, 1992
In the citing paper
“p53 is an crucial tumor suppressor that is mutated in more than 50% of human cancers”
From USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 (2010) · cites this paper as Lane, 1992
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893
Research works printed but not linked: 3
- Sturzbecher, H.-W. Oncogene (in the press).
- Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Cancer Res. 51, 6304–6311 (1991).
- Bischoff, F. Z. et al. Cancer Res. 50, 7979–7984 (1990).
Cited by
Items 401–500 of 1,031
Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53
Albrechtsen, N., Dornreiter, I., Grosse, F., Kim, E., Wiesmüller, L., & Deppert, W. (1999) · Oncogene · doi:10.1038/sj.onc.1202952 · Cited by 182
“This function of p53 led to the now famous coining of p53 as the `guardian of the genome' by Lane (1992).”
Backgroundp53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail.
Strickler, J. G., Zheng, J., Shu, Q., Burgart, L. J., Alberts, S. R., & Shibata, D. K. (1994) · PubMed · Cited by 195
Strasser, A., Huang, D. C. S., & Vaux, D. L. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00019-x · Cited by 180
Expression and prognostic significance of immunoregulatory molecules in esophageal cancer
Hosch, S. B., Izbicki, J. R., Pichlmeier, U., Stoecklein, N. H., Niendorf, A., Knoefel, W. T., Broelsch, C. E., & Pantel, K. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971219)74:6<571::aid-ijc2>3.0.co;2-r · Cited by 46
Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome.
Rotter, V, Schwartz, D., Almon, E., Goldfinger, N., Kapon, A., Meshorer, A., Donehower, L. A., & Levine, A. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.9075 · Cited by 181
Regulating the p53 system through ubiquitination
Yang, Y., Li, C.-C. H., & Weissman, A. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207411 · Cited by 179
“It has become clear now that p53 is a major ‘guardian of the genome’ (Lane, 1992).”
BackgroundThe influence of lysosomal stability of silver nanomaterials on their toxicity to human cells
Setyawati, M. I., Yuan, X., Xie, J., & Leong, D. T. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.007 · Cited by 178
“Depends on the severity of oxidative stress, p53 modulates antioxidative defense, arrests cell cycle progression, initiates DNA repair mechanism and instigates the programmed cell death [47,48].”
BackgroundJones, D. L., & Münger, K. (1997) · Journal of Virology · doi:10.1128/jvi.71.4.2905-2912.1997 · Cited by 146
Seluanov, A., Gorbunova, V., Falcovitz, A., Sigal, A., Milyavsky, M., Zurer, I., Shohat, G., Goldfinger, N., & Rotter, V. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1552-1564.2001 · Cited by 178
Crystal Structure of a Superstable Mutant of Human p53 Core Domain
Joerger, A. C., Allen, M. D., & Fersht, A. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309732200 · Cited by 163
Apoptosis and chemotherapy resistance
Hickman, J. A. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00080-9 · Cited by 180
p53-Mediated apoptosis is attenuated in Werner syndrome cells
Spillare, E. A., Robles, A. I., Wang, X. W., Shen, J.-C., Yu, C.-E., Schellenberg, G. D., & Harris, C. C. (1999) · Genes & Development · doi:10.1101/gad.13.11.1355 · Cited by 178
“The tumor suppressor gene product p53 plays a critical role in maintaining the genomic integrity of mammalian cells (Lane 1992).”
Backgroundp53 Regulation of Metabolic Pathways
Gottlieb, E., & Vousden, K. H. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001040 · Cited by 178
Maxwell, S. A., & Davis, G. E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.230445997 · Cited by 179
DNA repair processes are critical mediators of p53-dependent tumor suppression
Janic, A., Valente, L. J., Wakefield, M. J., Di Stefano, L., Milla, L., Wilcox, S., Yang, H., Tai, L., Vandenberg, C. J., Kueh, A. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0043-5 · Cited by 179
Early Growth Response-1-dependent Apoptosis Is Mediated by p53
Nair, P., Muthukkumar, S., Sells, S. F., Han, S.-S., Sukhatme, V. P., & Rangnekar, V. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.32.20131 · Cited by 176
Bettendorf, O., Piffkò, J., & Bànkfalvi, A. (2004) · Oral Oncology · doi:10.1016/j.oraloncology.2003.08.010 · Cited by 176
Macleod, K. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00041-6 · Cited by 173
p53 mutation is a common genetic event in ovarian carcinoma.
Milner, B. J., Allan, L. A., Eccles, D., Kitchener, H. C., Léonard, R., Kelly, K. F., Parkin, D. E., & Haites, N. E. (1993) · PubMed · Cited by 175
Stengel, A., Schnittger, S., Weissmann, S., Kuznia, S., Kern, W., Kohlmann, A., Haferlach, T., & Haferlach, C. (2014) · Blood · doi:10.1182/blood-2014-02-558833 · Cited by 176
Genetic pathways in colorectal and other cancers
Ilyas, M., Straub, J., Tomlinson, I. P. M., & Bodmer, W. F. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00298-1 · Cited by 174
p53 protects against skin cancer induction by UV-B radiation
Jiang, W., Ananthaswamy, H. N., Muller, H. K., & Kripke, M. L. (1999) · Oncogene · doi:10.1038/sj.onc.1202789 · Cited by 175
“In addition, p53 activates a pathway of programmed cell death, presumably in cells with excessive DNA damage (Lane, 1992).”
BackgroundThe regulation of MDM2 oncogene and its impact on human cancers
Zhao, Y., Yu, H., & Hu, W. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt147 · Cited by 173
Léveillard, T., Andera, L., Bissonnette, N., Schaeffer, L., Bracco, L., Egly, J. M., & Wasylyk, B. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00506.x · Cited by 173
General aspects of the cellular response to low- and high-LET radiation
Pouget, J.-P., & Mather, S. J. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100484 · Cited by 173
Han, I., Roos, M. D., & Kudlow, J. E. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19980101)68:1<50::aid-jcb5>3.0.co;2-v · Cited by 46
Allegra, C. J., Parr, A. L., Wold, L. E., Mahoney, M. R., Sargent, D. J., Johnston, P., Klein, P., Behan, K., O’Connell, M. J., Levitt, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.080 · Cited by 170
Payne, C. M., Bernstein, C., & Bernstein, H. (1995) · Leukemia & Lymphoma · doi:10.3109/10428199509059662 · Cited by 175
Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium.
Firestein, G. S., Nguyen, K., Aupperle, K. R., Yeo, M., Boyle, D. L., & Zvaifler, N. J. (1996) · Europe PMC (PubMed Central) · Cited by 190
Mechanisms of mutation formation with long‐wave ultraviolet light (UVA)
Rünger, T. M., & Kappes, U. P. (2008) · Photodermatology, Photoimmunology & Photomedicine · doi:10.1111/j.1600-0781.2008.00319.x · Cited by 171
Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants
Fortuno, C., Lee, K., Olivier, M., Pesaran, T., Mai, P. L., Andrade, K. C., Attardi, L. D., Crowley, S., Evans, D. G., Feng, B., et al. (2021) · Human Mutation · doi:10.1002/humu.24152 · Cited by 167
“The TP53 gene encodes p53, a protein with essential roles in genome stability and key cellular functions, such as cell cycle, metabolism, apoptosis, senescence, and differentiation (Lane, 1992; Zerdoumi et al., 2017).”
BackgroundHammerlid, E., Silander, E., H�rnestam, L., & Sullivan, M. (2001) · Head & Neck · doi:10.1002/1097-0347(200102)23:2<113::aid-hed1006>3.0.co;2-w · Cited by 368
Van Triest, B., Pinedo, H. M., Giaccone, G., & Peters, G. J. (2000) · Annals of Oncology · doi:10.1023/a:1008351221345 · Cited by 169
“vated wt p53 can also induce various targets including cyclin G, the damage response genes Gadd45 and ERCC3, and bax, a cell death promoting gene [33-35].”
BackgroundTricot, G., Sawyer, J. R., Jagannath, S., Desikan, K. R., Siegel, D., Naucke, S., Mattox, S., Bracy, D., Munshi, N., & Barlogie, B. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2659 · Cited by 172
Haanen, C., & Vermes, I. (1995) · Mediators of Inflammation · doi:10.1155/s0962935195000020 · Cited by 172
High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer
Holstege, H., Joosse, S. A., van Oostrom, C. T. M., Nederlof, P. M., de Vries, A., & Jonkers, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3426 · Cited by 171
Chi, S.-W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.16.4438 · Cited by 169
“…normally, but have a greater susceptibility to a variety of cancers (Malkin et al., 1990; Donehower et al., 1992), indicating that p53 is not essential for normal development, but rather exerts a crucial checkpoint function preventing deleterious genomic damage from being propagated (Lane, 1992).”
BackgroundMartı́n, D., Salinas, M., Fujita, N., Tsuruo, T., & Cuadrado, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201070200 · Cited by 168
Bladier, C., Wolvetang, E. J., Hutchinson, P. E., de Haan, J. B., & Kola, I. (1997) · PubMed · Cited by 196
Hamelin, R., Fléjou, J.-F., Muzeau, F., Potet, F., Laurent-Puig, P., Fékété, F., & Thomas, G. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90225-9 · Cited by 168
p53 and disease: when the guardian angel fails
Royds, J. A., & Iacopetta, B. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401913 · Cited by 168
Pathophysiology of ocular surface squamous neoplasia
Gichuhi, S., Ohnuma, S.-I., Sagoo, M. S., & Burton, M. J. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.10.015 · Cited by 161
“It is thus described as the ‘guardian of the genome’ (Lane, 1992).”
BackgroundIdentification of a Novel p53 Functional Domain That Is Necessary for Mediating Apoptosis
Zhu, J., Zhou, W., Jiang, J., & Chen, X. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13030 · Cited by 166
Merlo, G. R., Basolo, F., Fiore, L., Duboc, L., & Hynes, N. E. (1995) · The Journal of cell biology · doi:10.1083/jcb.128.6.1185 · Cited by 166
The role of DNA damage responses in p53 biology
Speidel, D. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1459-z · Cited by 160
“The Tp53 gene, encoding for the tumour suppressor protein p53, has, for a long time, been regarded a prime example illustrating the crucial relationship between DNA responses and tumour suppression (Lane 1992; Vogelstein et al. 2000).”
BackgroundKounelis, S., Kapranos, N., Kouri, E., Coppola, D., Papadaki, H., & Jones, M. W. (2000) · Modern Pathology · doi:10.1038/modpathol.3880062 · Cited by 166
“Wild type p53 protein contributes to tumor suppression through both arrest of cell proliferation and induction of cell death through apoptosis (9, 10).”
Workman, P. (1995) · Human & Experimental Toxicology · doi:10.1177/096032719501400213 · Cited by 165
Targeting protein–protein interactions by rational design: mimicry of protein surfaces
Fletcher, S., & Hamilton, A. D. (2006) · Journal of The Royal Society Interface · doi:10.1098/rsif.2006.0115 · Cited by 164
“The human double minute 2 (HDM2) protein regulates the cellular levels of p53, a protein that is known to play a key role in the apoptosis pathway (Lane 1992).”
BackgroundGottlieb, E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.6.1381 · Cited by 166
“C57BL/6, 25% 129/Sv genetic background (Donehower et al., 1992) It has been noted early on that mice heterozygous were kindly provided by L.Donehower through V.Rotter. for p53 are more prone to cancer than p53 / mice (Donehower et al., 1992; Kemp et al., 1993; Jacks et al., Generation of transgenic…”
InfluentialExpression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.
Lee, J. S., Yoon, A., Kalapurakal, S. K., Ro, J. Y., Lee, J. J., Tu, N., Hittelman, W. N., & Hong, W. K. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1893 · Cited by 163
Bakalkin, G., Selivanova, G., Yakovleva, T., Kiseleva, E., Kashuba, E., Magnusson, K. P., Szekely, L., Klein, G., Terenius, L., & Wiman, K. G. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.3.362 · Cited by 164
E2F-1:DP-1 Induces p53 and Overrides Survival Factors To Trigger Apoptosis
Hiebert, S. W., Packham, G., Strom, D. K., Haffner, R., Oren, M., Zambetti, G., & Cleveland, J. L. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6864 · Cited by 163
Seymour, J. F., Kipps, T. J., Eichhorst, B. F., D’Rozario, J., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., et al. (2022) · Blood · doi:10.1182/blood.2021015014 · Cited by 159
p53-dependent ceramide response to genotoxic stress.
Dbaibo, G. S., Pushkareva, M. Y., Rachid, R. A., Alter, N., Smyth, M. J., Obeid, L. M., & Hannun, Y. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1180 · Cited by 162
“The integrity of these cellular defense functions is crucial for maintenance of an intact genome and, therefore, p53 has been called the “guardian of the genome” (21).”
Prognostic significance of TP53 alterations in breast carcinoma
Andersen, T., Holm, R., Nesland, J., Heimdal, K., Ottestad, L., & Børresen, A. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.383 · Cited by 168
Gottlieb, E., Haffner, R., von Rüden, T., Wagner, E. F., & Oren, M. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06390.x · Cited by 163
Inactivation of the p53-homologue p73 by the mdm2-oncoprotein
Dobbelstein, M., Wienzek, S., König, C., & Roth, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202512 · Cited by 161
“Possibly, p73 may act as a regulator of di erentiation in a subset of tissues, rather than as a general `guardian of the genome' (Lane, 1992).”
BackgroundHigh Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
Carr-Wilkinson, J., O'Toole, K., Wood, K. M., Challen, C. C., Baker, A. G., Board, J. R., Evans, L., Cole, M., Cheung, N.-K. V., Boos, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1865 · Cited by 162
p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways
Lindström, M. S., Bartek, J., & Maya-Mendoza, A. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00999-w · Cited by 159
Davison, T. S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., & Arrowsmith, C. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18709 · Cited by 160
Human Papillomavirus Oncoproteins E6 and E7 Independently Abrogate the Mitotic Spindle Checkpoint
Thomas, J. T., & Laimins, L. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1131-1137.1998 · Cited by 162
Caught in the cross fire: p53 in inflammation
Cooks, T., Harris, C. C., & Oren, M. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu134 · Cited by 162
Involvement of p53 in cell differentiation and development
Almog, N., & Rotter, V. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00012-7 · Cited by 162
Khan, R., & Sultana, S. (2011) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2011.03.009 · Cited by 161
Schuijer, M., & Berns, E. M. J. J. (2003) · Human Mutation · doi:10.1002/humu.10181 · Cited by 160
“Aberrations in the repair mechanism, in which wild-type TP53 (MIM# 191170) as the ‘‘guardian of the genome’’ [Lane, 1992] contributes directly and indirectly, might lead to unrestrained proliferation and neoplasia.”
BackgroundGenetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications
Smith, J. (2000) · Frontiers in Bioscience · doi:10.2741/smith · Cited by 160
Apolinario, R. M., van der Valk, P., de Jong, J. S., Deville, W., van Ark-Otte, J., Dingemans, A. M., van Mourik, J. C., Postmus, P. E., Pinedo, H. M., & Giaccone, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2456 · Cited by 161
Unravelling the mechanisms regulating muscle mitochondrial biogenesis
Hood, D. A., Tryon, L. D., Carter, H. N., Kim, Y., & Chen, C. C. W. (2016) · Biochemical Journal · doi:10.1042/bcj20160009 · Cited by 159
Przygodzki, R. M., Finkelstein, S. D., Langer, J., SWALSKY, P., Fishback, N. F., Bakker, A., Guinee, D. G., Koss, M., & Travis, W. D. (1996) · PubMed · Cited by 159
Alpha-particle-induced p53 protein expression in a rat lung epithelial cell strain.
Hickman, A. W., Jaramillo, R. J., Lechner, J. F., & Johnson, N. (1994) · PubMed · Cited by 159
Regulation and Mechanisms of Mammalian Gene Amplification
(1993) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60956-2 · Cited by 160
Effect of zinc oxide nanomaterials-induced oxidative stress on the p53 pathway
Setyawati, M. I., Tay, C. Y., & Leong, D. T. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.024 · Cited by 158
p53 Plays a Role in Mesenchymal Differentiation Programs, in a Cell Fate Dependent Manner
Molchadsky, A., Shats, I., Goldfinger, N., Pevsner-Fischer, M., Olson, M., Rinon, A., Tzahor, E., Lozano, G., Zipori, D., Sarig, R., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003707 · Cited by 161
“[1].”
Role of Type 2C Protein Phosphatases in Growth Regulation and in Cellular Stress Signaling
Lammers, T., & Lavi, S. (2007) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230701693342 · Cited by 158
“…it was found that PP2Cα was able to induce both the expression and the transcriptional activity of p53, the so called ‘guardian of the genome’ (Lane, 1992), and undoubtedly one of the most important regulators of cell growth and cellular stress signaling (Levine, 1997; Vogelstein et al.,…”
BackgroundO'Connor, P. M., Ferris, D. K., Pagano, M., Draetta, G., Pines, J., Hunter, T., Longo, D. L., & Kohn, K. W. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53096-9 · Cited by 158
The role of tumor suppressor p53 in the antioxidant defense and metabolism
Budanov, A. V. (2014) · Subcellular Biochemistry · doi:10.1007/978-94-017-9211-0_18 · Cited by 157
“As a result, p53 induces cell cycle arrest, stimulates DNA-repair and protects genomic stability earning p53 the name “guardian of the genome” (Lane, 1992).”
Backgroundp53 is balancing development, differentiation and de-differentiation to assure cancer prevention
Molchadsky, A., Rivlin, N., Brosh, R., Rotter, V., & Sarig, R. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq101 · Cited by 156
Prognostic impact of p21/waf1/cip1 in colorectal cancer
Zirbes, T. K., Baldus, S. E., Moenig, S. P., Nolden, S., Kunze, D., Shafizadeh, S. T., Schneider, P. M., Thiele, J., Hoelscher, A. H., & Dienes, H. P. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000120)89:1<14::aid-ijc3>3.0.co;2-l · Cited by 98
Lipponen, P., Pietiläinen, T., Kosma, V., Aaltomaa, S. H., Eskelinen, M., & Syrjäunen, K. (1995) · The Journal of Pathology · doi:10.1002/path.1711770109 · Cited by 167
Dietary fibre and colorectal cancer: A model for environment – gene interactions
Young, G. P., Hu, Y., Le Leu, R. K., & Nyskohus, L. (2005) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500026 · Cited by 155
Early stages of p53-induced apoptosis are reversible
Geske, F. J., Lieberman, R., Strange, R., & Gerschenson, L. E. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400786 · Cited by 159
“In the present study, we focus on p53, a key molecule in apoptosis and maintenance of genomic integrity.(38) Our results show that early stages of p53-induced apoptosis are reversible if the apoptotic stimulus is removed.”
Brummelkamp, T. R., Kortlever, R. M., Lingbeek, M., Trettel, F., MacDonald, M. E., van Lohuizen, M., & Bernards, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110492200 · Cited by 154
Fichtner, I., Slisow, W., Gill, J. H., Becker, M., Elbe, B., Hillebrand, T., & Bibby, M. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.10.011 · Cited by 156
Hsp90 Regulates the Activity of Wild Type p53 under Physiological and Elevated Temperatures
Müller, L., Schaupp, A., Walerych, D., Wegele, H., & Buchner, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407687200 · Cited by 155
Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases.
Milne, D. M., Campbell, D. G., Caudwell, F. B., & Meek, D. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37101-6 · Cited by 156
Drugging the addict: non‐oncogene addiction as a target for cancer therapy
Nagel, R., Semenova, E. A., & Berns, A. J. M. (2016) · EMBO Reports · doi:10.15252/embr.201643030 · Cited by 175
Regulation of histone modification and chromatin structure by the p53–PADI4 pathway
Tanikawa, C., Espinosa‐Cantellano, M., Suzuki, A., Masuda, K., Yamamoto, K., Tsuchiya, E., Ueda, K., Daigo, Y., Nakamura, Y., & Matsuda, K. (2012) · Nature Communications · doi:10.1038/ncomms1676 · Cited by 166
Ball, K. L., Laín, S., Fåhræus, R., Smythe, C., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00029-7 · Cited by 171
Self-citationHardcastle, I. R., Liu, J., Valeur, E., Watson, A., Ahmed, S. U., Blackburn, T. J., Bennaceur, K., Clegg, W., Drummond, C., Endicott, J. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1011929 · Cited by 151
p53 and metabolism: from mechanism to therapeutics
Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 171
DNA damage induces p53-independent apoptosis through ribosome stalling
Boon, N. J., Oliveira, R. A., Körner, P.-R., Kochavi, A., Mertens, S., Malka, Y., Voogd, R., van der Horst, S. E. M., Huismans, M. A., Smabers, L. P., et al. (2024) · Science · doi:10.1126/science.adh7950 · Cited by 170
Human p53 Binds Holliday Junctions Strongly and Facilitates Their Cleavage
Lee, S., Cavallo, L., & Griffith, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.11.7532 · Cited by 153
Olovnikov, I. A., Kravchenko, J. E., & Chumakov, P. M. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.005 · Cited by 153
Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation
Zhang, Z., & Zhang, R. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.25 · Cited by 153
“Tumor suppressor p53 is involved in controlling cell growth and differentiation and in the maintenance of genomic in- tegrity, with high levels of p53 activity inducing apoptosis, cell cycle arrest, or senescence (Lane, 1992).”
Backgroundp53-Mediated Germ Cell Quality Control in Spermatogenesis
Yin, Y., Stahl, B. C., DeWolf, W. C., & Morgentaler, A. (1998) · Developmental Biology · doi:10.1006/dbio.1998.9074 · Cited by 174
Zauberman, A., Barak, Y., Ragimov, N., Levy, N., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05941.x · Cited by 173
p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome
Spike, B. T., & Wahl, G. M. (2011) · Genes & Cancer · doi:10.1177/1947601911410224 · Cited by 135
Targeting apoptotic pathways for cancer therapy
Tian, X., Srinivasan, P. R., Tajiknia, V., Uruchurtu, A. S. S., Seyhan, A. A., Carneiro, B. A., Cruz, A. D. L., Pinho-Schwermann, M. P., George, A., Zhao, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179570 · Cited by 172
Esthesioneuroblastoma: Reflections of a 21‐Year Experience
Levine, P. A., Gallagher, R. M., & Cantrell, R. W. (1999) · The Laryngoscope · doi:10.1097/00005537-199910000-00001 · Cited by 154
Poller, D. N., Roberts, E., Bell, J. A., Elston, C. W., Blamey, R. W., & Ellis, I. O. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90157-c · Cited by 150
Metadata
- Authors
- Lane, D. P.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Lane, D. P.
- ORCID
- Lane, D. P.
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 15-16
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2012053348
- Cited by
- 5,138
- References
- 19
- Citations by year
- 2026: 84 · 2025: 92 · 2024: 122 · 2023: 112 · 2022: 135 · 2021: 142 · 2020: 150 · 2019: 128 · 2018: 140 · 2017: 138 · 2016: 142 · 2015: 135 · 2014: 150 · 2013: 142 · 2012: 143
- FWCI
- 97.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- TP53, p53, TP53 mutation, cancer, genome stability, tumor suppressor
- MeSH terms
- Animals, Chromosome Mapping, DNA Damage, DNA Repair, DNA-Binding Proteins, Gene Expression Regulation, Humans, Oncogenes, Transcription Factors, Genes, Tumor Suppressor, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.